Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients

Author(s):
Lemos, C.; Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Scheffer, G.L.; Straaten, T. van der; D'Incecco, A.; Falcone, A.; Guchelaar, H.J. (0000-0002-7085-1383); Danesi, R.; Santoro, A.; Giaccone, G.; Tibaldi, C.; Peters, G.J.
Published
2011
Publication type
Article / Letter to editor
ABCG2gefitiniblung cancerpharmacogeneticstoxicity
Date issued
2011-02-28
Language
English
Is part of
Pharmacogenomics (2011), Vol. 12, no. 2, p. 159-170
hdl
1887/109310
doi
10.2217/pgs.10.172